ERBB2 and gastroesophageal junction adenocarcinoma: The trial found that ZOL-FO significantly prolonged OS [median OS, 18.23 vs 15.54 months, HR0.75(95%CI 0.60–0.94)] and PFS [median PFS, 10.61 vs 8.67 months, HR0.75(95%CI 0.60–0.94)] in CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma compared with PLB-FO in safely and manageably, providing a new first-line treatment option for advanced G/GEJ adenocarcinoma.